Digital Health Technologies (DHTs) in Clinical Trials: Key Points from the FDA’S Important Draft Guidance Date Published: Jan 27, 2022 Whitepaper Signant’s Bill Byrom discusses the FDA’s most recent guidelines regarding DHTs, such as sensors and wearables as well as general computing platforms, when collecting health data from clinical trial patients. Readers will learn: The FDA’s position on BYOD in the context of DHTsThe evidence supporting the use of sensors & wearablesData integrity considerations in the context of minimizing missing data and device, firmware, or software update Download Now Share: LinkedInTweet Recommended Resources The EMA Recommendation Paper on Decentralized Elements in Clinical Trials: An Overview Read Our White Paper Whitepaper Optimal COA Measurement Strategy in Modern Oncology Trials Read Our White Paper Whitepaper Site Perspectives on BYOD ePRO Use Download Whitepaper